Satellos Bioscience (MSLE) Other Non-Current Liabilities (2025 - 2026)
Satellos Bioscience's (MSLE) quarterly Other Non-Current Liabilities came in at $19.3 million in Q1 2026, up 24.84% on a QoQ basis from $15.5 million in Q4 2025.
Satellos Bioscience (MSLE) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Other Non-Current Liabilities data on file, last reported at $19.3 million in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $19.3 million in Q1 2026; TTM through Mar 2026 was $19.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $15.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $19.3 million, up from $15.5 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for MSLE reached as high as $19.3 million in Q1 2026 and fell as low as $15.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn |
| 10 | Satellos Bioscience | 175.96 Mn | 175.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.33 Mn |
| Dec 31, 2025 | 15.48 Mn |